High-resolution proteomics data from tissue and urine enable the identification of protein changes in pathological conditions, combined with extensive literature data can target the disease associated molecular pathways. Key components of these pathways can be then verified in human tissue. This builds a foundation for the identification of biology-driven therapeutic targets.
The proposed context of use of proteomics profiling :
a) patients’ diagnosis and monitoring (for urinary biomarkers) and
b) the identification of novel therapeutic targets and prediction of treatment response (tissue profiling/ urine biomarkers).
In actual application, classifiers to predict the response to the known drugs are expected to be applied, in order to provide a score depicting the likelihood of response to the respective drug. Consequently, the drug with highest scoring will be chosen for therapy, to increase the success rate of the therapy. In the next step, classifiers to predict the disease progression and also monitor the treatment effect in a non-invasive way are applied. In case of a positive result for disease progression, alternative/ more efficient treatment will be then selected.
BioMedBC is a Marie Sklodowska Curie Actions (MSCA) Individual Fellowship programme (H2020-MSCA-IF-2016)
funded by the European Union under the Horizon2020 Framework Programme (Grant Agreement:752755) and
coordinated by Mosaiques diagnostics